AU760967B2 - Herbal composition for the prophylaxis and treatment of AIDS - Google Patents
Herbal composition for the prophylaxis and treatment of AIDS Download PDFInfo
- Publication number
- AU760967B2 AU760967B2 AU68125/98A AU6812598A AU760967B2 AU 760967 B2 AU760967 B2 AU 760967B2 AU 68125/98 A AU68125/98 A AU 68125/98A AU 6812598 A AU6812598 A AU 6812598A AU 760967 B2 AU760967 B2 AU 760967B2
- Authority
- AU
- Australia
- Prior art keywords
- stephania
- aids
- composition
- menispermaceae
- zingiberaceae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims description 37
- 208000030507 AIDS Diseases 0.000 title claims description 28
- 238000011282 treatment Methods 0.000 title claims description 25
- 238000011321 prophylaxis Methods 0.000 title claims description 19
- 241000218164 Menispermaceae Species 0.000 claims description 27
- 235000018453 Curcuma amada Nutrition 0.000 claims description 19
- 241001512940 Curcuma amada Species 0.000 claims description 19
- 244000050907 Hedychium coronarium Species 0.000 claims description 19
- 241001094090 Stephania venosa Species 0.000 claims description 19
- 244000273928 Zingiber officinale Species 0.000 claims description 19
- 241001300620 Stephania suberosa Species 0.000 claims description 18
- 206010001513 AIDS related complex Diseases 0.000 claims description 14
- 241000196324 Embryophyta Species 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 235000012054 meals Nutrition 0.000 claims description 6
- 235000008216 herbs Nutrition 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 239000007903 gelatin capsule Substances 0.000 claims description 3
- 208000037357 HIV infectious disease Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000242 pagocytic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 12
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 208000001388 Opportunistic Infections Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 241001330502 Stephania Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
WO 99/51249 PCT/AU98/00236 1 Herbal Composition for the Prophylaxis and Treatment of AIDS The present invention is in the fields of medicine and pharmacology. In particular the present invention relates to herbal composition for the prophylaxis and treatment of human immunodeficiency virus (HIV) disease and Acquired Immune Deficiency Syndrome (AIDS) and AIDS related complex.
TECHNICAL FIELD Acquired Immune Deficiency Syndrome (AIDS) is a pandemic immunosuppressive disease which results in life threatening opportunistic infection and malignancies. The disease kills the helper cells of the immune system which play a crucial role in cell mediated immunity. The progressive loss of the helper cells in the blood leads to a stage where the body is rendered incapable of resisting many bacterial, viral and parasitical invasions resulting in the AIDS patient dying from opportunistic infections. A retrovirus, designated human immunodeficiency virus (HIV-1), has been isolated and identified as the etiologic agent of this disease.
It was estimated that there were about 23 millions HIV infected patients all over the world in 1997. Of these patients, 90% live in developing countries with Asia having the highest numbers of newly infected patients.
Several agents have been reported to inhibit the growth of the human immunodeficiency virus. These include nucleoside analog reverse Transcriptase inhibitors (NRTIs) e.g. zidovudine, lamivudine, d4T (trade names) and protease inhibitors e.g. indinavir, ritonavir, nelfinavir (trade names). A combination of drugs may be used, for example 3 drug regimens that usually include 2 nucleoside analog reverse transcriptase inhibitors and a protease inhibitor, but they are complex and costly. Furthermore these compounds appear to be too toxic for prolonged use or only have a limited capability of minimising or eliminating HIV infections from the human host.
Accordingly the currently known anti-HIV drugs now available are costly and potentially toxic and inaccessible to the majority of HIV infected patients in SUBSTITUTE SHEET (RULE 26) 2 developing countries. Therefore all patients need less expensive, less toxic and effective anti-HIV drugs.
Herbal preparations/ treatments and medicines have been used for the treatment of various diseases in Thailand and South East Asia for several hundred years. Recent interest in natural treatment for health problems has resulted in herbal drugs being researched as to their chemical constituents, toxicity and activities.
The object of the present invention is to provide a herbal composition for the prophylaxis and treatment of AIDS and/or a method for the prophylaxis and treatment of AIDS patients using that herbal composition.
By the terms HIV and AIDS related virus is meant the commonly designated HIV series (human immunodeficiency virus) formerly called HTLV, LAV and ARV, and species thereof.
DISCLOSURE OF THE INVENTION In one form of this invention there is proposed a method for the prophylaxis and treatment of AIDS and AIDS related complex comprising the step of administering to an animal or person a therapeutically effective amount of a preparation including an extract of one or more of the following plants; Stephania venosa Spreng, Stephania suberosa Forman, Stephania glabra 20 Roxb. Miers., Hedychium coronarium Roem, Zingiber officinalis Roscoe and Curcurma Amada.
In a further form of the invention there is proposed a composition for the prophylaxis and treatment of AIDS and AIDS related complex including an extract of one or more of the following plants; Stephania venosa Spreng, 25 Stephania suberosa Forman, Stephania glabra Roxb. Miers., Hedychium coronarium Roem, Zingiber officinalis Roscoe and Curcurma Amada.
In a further form of the invention there is proposed a method of inhibiting in "i vitro HIV infection in human T lymphocyte cells and mononuclear phagocytic lineage cells infected with HIV with a preparation consisting essentially of an extract from the following Stephania venosa Spreng, Stephania WO 99/51249 PCT/AU98/00236 3 suberosa Forman, Stephania glabra Roxb. Miers., Hedychium coronarium Roem, Zingiber officinalis Roscoe and Curcurma Amada.
In a yet further form of the invention there is proposed a composition for the prophylaxis and treatment of AIDS and AIDS related complex comprising a therapeutically acceptable composition of herbs comprising 18.0 to 19.0% of the total weight of the following formulated by weight of each of Stephania venosa Spreng, Hedychium coronarium Roem, 16.0 to 17.0% by weight of each of Stephania suberosa Forman, Stephania glabra Roxb. Miers and 14.5 to 15.5% by weight of each of Zingiber officinalis Roscoe, Curcurma Amada.
In a yet still further form of the invention there is proposed a composition for the prophylaxis and treatment of AIDS and AIDS related complex comprising each of the following of selected dried plant material in the proportions selected hereafter: Name of herb Classification Weight (mg) minimum Stephania venosa Spreng Stephania suberosa Forman Stephania glabra Roxb. Miers.
Hedychium coronarium Roem Zingiber officinalis Roscoe Curcurma Amada
(MENISPERMACEAE)
(MENISPERMACEAE)
(MENISPERMACEAE)
(ZINGIBERACEAE)
(ZINGIBERACEAE)
(ZINGIBERACEAE)
It is to be understood though that the particular weight of each plant may depending on the potency of each plant.
In a further still form of the invention there is proposed a composition for the prophylaxis and treatment of AIDS and AIDS related complex comprising the following, as dried plant materials Name of herb Classification Weight (mg) Stephania venosa Spreng Stephania suberosa Forman Stephania glabra Roxb. Miers.
(MENISPERMACEAE)
(MENISPERMACEAE)
(MENISPERMACEAE)
SUBSTITUTE SHEET (RULE 26) WO 99/51249 PCT/AU98/00236 Hedychium coronarium Roem Zingiber officinalis Roscoe Curcurma Amada
(ZINGIBERACEAE)
(ZINGIBERACEAE)
(ZINGIBERACEAE)
In preference the composition is in the form of a capsule, said capsule being preferentially a gelatin capsule.
In preference the composition is in the form of a liquid mixed with a syrup.
In a still further form of the invention there is proposed a process for preparing a composition for the prophylaxis and treatment of AIDS and AIDS related complex including: 0 pulverising into powder the following amounts of dried plant material consisting essentially of: Name of herb Classification Weight(mg) range Stephania venosa Spreng Stephania suberosa Forman Stephania glabra Roxb. Miers.
Hedychium coronarium Roem Zingiber officinalis Roscoe Curcurma Amada
(MENISPERMACEAE)
(MENISPERMACEAE)
(MENISPERMACEAE)
(ZINGIBERACEAE)
(ZINGIBERACEAE)
(ZINGIBERACEAE)
40-60 40-60 40-60 40-60 30-50 30-50 preparing a pharmaceutical formulation comprising the powder of step (a) In preference the total weight of the composition of Stephania venosa Spreng, Stephania suberosa Forman, Stephania glabra Roxb. Miers., Hedychium coronarium Roem, Zingiber officinalis Roscoe and Curcurma Amada is no more than 300 mgs.
In preference the method includes giving the composition in the quantities stated twice a day before meals to a patient (human adult) who weighs 60 kg or less.
SUBSTITUTE SHEET (RULE 26) WO 99/51249 PCT/AU98/00236 In preference the method includes giving the composition three times a day before meals to a patient (human adult) who weighs 60-100 kg.
BEST MODE OF THE INVENTION The following detailed description and procedures are provided to illustrate the principles of the invention. They are not, however, intended to limit this invention.
After a significant period of trial and modification a mixture of the following herbs was found to be successful for treating AIDS patients.
Name of Herb Classification Stephania venosa Spreng (MENISPERMACEAE) Stephania suberosa Forman (MENISPERMACEAE) Stephania glabra Roxb. Miers. (MENISPERMACEAE) Hedychium coronarium Roem (ZINGIBERACEAE) Zingiber officinalis Roscoe (ZINGIBERACEAE) Curcurma Amada (ZINGIBERACEAE) Each herb was collected fresh, was washed with water, cut into small pieces, dried and separated from all extraneous material. Each herb was weighed according to predetermined proportions and pulverised together into a powder of about 40-100 mesh, and dried again. However, it is to be understood that the extracts from each subject herb can be used and prepared by known organic extraction procedures.
The resulting herbal powder composition is then filled into hard gelatin capsules. The combination of the herbal composition with an appropriate solid carrier, such as lactose, starch, and lubricants magnesium stearate, calcium stearate) or the like can be used. Each capsule contained approximately 300 mg of the herbal powder composition.
The dosage for oral use chosen for trials is one capsule, twice a day before meals for a patient who weighs 60 kg or lower, and for a patient who weighs 60 to 100 kg, one capsule is administered three times a day before meals.
SUBSTITUTE SHEET (RULE 26) WO 99/51249 PCT/AU98/00236 6 From experiments conducted so far, a therapeutically effective quantify of the referred to composition for an average human adult is at least as follows Name of herb Classification Min wt (mg) Stephania venosa Spreng Stephania suberosa Forman Stephania glabra Roxb. Miers.
Hedychium coronarium Roem Zingiber officinalis Roscoe Curcurma Amada
(MENISPERMACEAE)
(MENISPERMACEAE)
(MENISPERMACEAE)
(ZINGIBERACEAE)
(ZINGIBERACEAE)
(ZINGIBERACEAE)
It has also been found that the above minimum weights can be some 20 mg for each herb.
In a first example the composition comprises the following increased by Name of herb Classification Weight (mg) Stephania venosa Spreng Stephania suberosa Forman Stephania glabra Roxb. Miers.
Hedychium coronarium Roem Zingiber officinalis Roscoe Curcurma Amada (MENISPERMACEAE) (MENISPERMACEAE) (MENISPERMACEAE) (ZINGIBERACEAE) (ZINGIBERACEAE) (ZINGIBERACEAE) Total 300 Over one hundred patients with confirmed cases of full blown AIDS or HIV infected were treated with the composition of this invention in AIDS treatment hospitals. Both before treatment and periodically after treatment all patients were tested for the following hemoglobin (Hb) white blood cells (WBC) platelet (Pit) polymorphonuclear (PMN) basophol (Bas) lymphocyte (Lymph) monocyte (Mono) SUBSTITUTE SHEET (RULE 26) WO 99/51249 PCT/AU98/00236 7 CD4, CD8, CD4/CD8 ratio as well as other physical conditions. It was found that most of the patients showed improved physical conditions and the symptoms of most opportunistic infections either reduced or significantly disappeared. Thus, approximately equal quantities of the herbs in the composition were found to give a therapeutic advantage.
SUBSTITUTE SHEET (RULE 26)
Claims (6)
1. A method for the prophylaxis and treatment of AIDS and AIDS related complex comprising the step of administering to an animal or a person a therapeutically effective amount of an extract of one or more of the following plants; Stephania venosa Spreng, Stephania suberosa Forman, Stephania glabra Roxb. Miers., Hedychium coronarium Roem, Zingiber officinalis Roscoe and Curcurma Amada.
2. A method of inhibiting in vitro HIV infection in human T lymphocyte cells and mononuclear phagocytic lineage cells infected with HIV with a preparation consisting essentially of an extract from one or more of the following plants; Stephania venosa Spreng, Stephania suberosa Forman, Stephania glabra Roxb. Miers., Hedychium coronarium Roem, Zingiber officinalis Roscoe and Curcurma Amada.
3. A composition for the prophylaxis/and treatment of AIDS and AIDS related complex including an extract from each of the following plants; Stephania venosa Spreng, Stephania suberosa Forman, Stephania glabra Roxb. Miers., Hedychium coronarium Roem, Zingiber officinalis Roscoe and Curcurma Amada. e*
4. A composition for the prophylaxis and treatment of AIDS and AIDS related S, 20 complex comprising a therapeutically acceptable composition of herbs comprising
18.0 to 19.0% of the total weight of the following formulated by weight of each of Stephania venosa Spreng, Hedychium coronarium Roem, 16.0 to 17.0% by weight of each of Stephania suberosa Forman, Stephania glabra Roxb. Miers and 14.5 to 15.5% by weight of each of Zingiber officinalis 25 Roscoe, Curcurma Amada. 5. A composition for the prophylaxis and treatment of AIDS and AIDS related complex comprising each of the following of selected dried plant material in the proportions selected hereafter: Name of herb Classification Weight (mg) minimum WO 99/51249 PCT/AU98/00236 Stephania venosa Spreng Stephania suberosa Forman Stephania glabra Roxb. Miers. Hedychium coronarium Roem Zingiber officinalis Roscoe Curcurma Amada (MENISPERMACEAE) (MENISPERMACEAE) (MENISPERMACEAE) (ZINGIBERACEAE) (ZINGIBERACEAE) (ZINGIBERACEAE) 6. A composition for the prophylaxis and treatment of AIDS and AIDS related complex comprising the following, as dried plant materials Name of herb Classification Weight (mg) Stephania venosa Spreng Stephania suberosa Forman Stephania glabra Roxb. Miers. Hedychium coronarium Roem Zingiber officinalis Roscoe Curcurma Amada (MENISPERMACEAE) (MENISPERMACEAE) (MENISPERMACEAE) (ZINGIBERACEAE) (ZINGIBERACEAE) (ZINGIBERACEAE) 7. A composition as claimed in any one of claims 3 to 6 being substantially in the form of a capsule. 8. A composition as in claim 7 wherein said capsule is a gelatin capsule. 9. A composition as claimed in any one of claims 3 to 6 wherein said composition is in the form of a liquid mixed with a syrup. A composition as in any one of claims 3 to 9 wherein the total combined weight of the extracts of Stephania venosa Spreng, Stephania suberosa Forman, Stephania glabra Roxb. Miers., Hedychium coronarium Roem, Zingiber officinalis Roscoe and Curcurma Amada is no more than 300 mgs. 11. A method of prophylaxis and treatment of AIDS and AIDS related complex including administering a composition as claimed in any one of claims 3 to 10 twice a day before meals to a patient (human adult) who weighs 60 kg or less. SUBSTITUTE SHEET (RULE 26) WO 99/51249 PCT/AU98/00236 12. A method of prophylaxis and treatment of AIDS and AIDS related complex including administering a composition as claimed in any one of claims 3 to 10 three times a day before meals to a patient (human adult) who weighs 60-100 kg. 13. A process for preparing a composition for the prophylaxis and treatment of AIDS and AIDS related complex including: pulverising into powder the following amounts of dried plant material consisting essentially of: Name of herb Classification Weight(mg) range Stephania venosa Spreng Stephania suberosa Forman Stephania glabra Roxb. Miers. Hedychium coronarium Roem Zingiber officinalis Roscoe Curcurma Amada (MENISPERMACEAE) (MENISPERMACEAE) (MENISPERMACEAE) (ZINGIBERACEAE) (ZINGIBERACEAE) (ZINGIBERACEAE)
40-60 40-60 40-60 40-60 30-50 30-50 preparing a pharmaceutical formulation comprising the powder of step SUBSTITUTE SHEET (RULE 26)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/AU1998/000236 WO1999051249A1 (en) | 1998-04-07 | 1998-04-07 | Herbal composition for the prophylaxis and treatment of aids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6812598A AU6812598A (en) | 1999-10-25 |
| AU760967B2 true AU760967B2 (en) | 2003-05-22 |
Family
ID=3764519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU68125/98A Ceased AU760967B2 (en) | 1998-04-07 | 1998-04-07 | Herbal composition for the prophylaxis and treatment of AIDS |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP2002510640A (en) |
| KR (1) | KR20010034764A (en) |
| CN (1) | CN1291103A (en) |
| AU (1) | AU760967B2 (en) |
| WO (1) | WO1999051249A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1363595A2 (en) * | 2001-01-19 | 2003-11-26 | Johnson & Johnson Consumer Companies, Inc. | Composition containing hedychium extract and use thereof |
| US20040052868A1 (en) | 2002-09-12 | 2004-03-18 | William Asiedu | Composition treating for AIDS and associated conditions |
| US7160561B2 (en) | 2003-05-19 | 2007-01-09 | Amazon Biotech Inc. | Herbal composition and method of treating HIV infection |
| EP2437766A1 (en) * | 2009-03-31 | 2012-04-11 | Erick Vidjin' Agnih Gbodossou | Water-soluble antiviral product containing aframomum melegueta, for the treatment and prevention of acquired immunodeficiency syndrome (aids) |
| JP6198427B2 (en) * | 2013-03-29 | 2017-09-20 | 小林製薬株式会社 | Oral composition containing gelatin |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3002700B2 (en) * | 1990-08-29 | 2000-01-24 | 化研生薬株式会社 | Anti-AIDS virus agent |
| US5683698A (en) * | 1996-08-02 | 1997-11-04 | New England Deaconess Hospital | Formulation for alleviating symptoms associated with arthritis |
-
1998
- 1998-04-07 WO PCT/AU1998/000236 patent/WO1999051249A1/en not_active Ceased
- 1998-04-07 CN CN98813948A patent/CN1291103A/en active Pending
- 1998-04-07 AU AU68125/98A patent/AU760967B2/en not_active Ceased
- 1998-04-07 KR KR1020007011188A patent/KR20010034764A/en not_active Withdrawn
- 1998-04-07 JP JP2000542020A patent/JP2002510640A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU6812598A (en) | 1999-10-25 |
| WO1999051249A1 (en) | 1999-10-14 |
| JP2002510640A (en) | 2002-04-09 |
| KR20010034764A (en) | 2001-04-25 |
| CN1291103A (en) | 2001-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| De Clercq | Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection | |
| Kao et al. | Podophyllotoxin intoxication: toxic effect of Bajiaolian in herbal therapeutics | |
| DE3886710T2 (en) | METHOD FOR SELECTIVE INHIBITION OF HIV. | |
| DE69738535T2 (en) | ANTIVIRAL AGENTS FROM PLANT EXTRACTS AND THEIR USE FOR THE TREATMENT OF VIRAL INFECTIONS | |
| Dzoyem et al. | Antimycobacterial activity against different pathogens and selectivity index of fourteen medicinal plants used in southern Africa to treat tuberculosis and respiratory ailments | |
| Chu et al. | Amebicidal activity of plant extracts from Southeast Asia on Acanthamoeba spp. | |
| Mugomeri et al. | Medicinal herbs used by HIV-positive people in Lesotho | |
| JPH03505325A (en) | Retroviral infection treatment | |
| AU760967B2 (en) | Herbal composition for the prophylaxis and treatment of AIDS | |
| JP7317309B2 (en) | Autophagic cell death inducer | |
| WO1994018993A1 (en) | Therapeutic herbal composition | |
| EP1629847B1 (en) | Herbal AIDS treatment | |
| WO2004112692A2 (en) | Therapeutic herbal compositions | |
| US6485759B2 (en) | Botanical combinations for treating AIDS and immune-deficient patients to maintain good health and the process for preparing the same | |
| US20040258712A1 (en) | Herbal composition containing sea salt | |
| RU2187326C1 (en) | Composition "vilarin" showing adaptogenic and general tonic effect | |
| Bone | Autoimmune disease: A phytotherapeutic perspective | |
| CN100371015C (en) | A kind of antiviral Chinese herbal medicine product | |
| Singh et al. | Evaluation of phytochemicals from Indian traditional medicinal plants as anti-HIV-1 Drugs | |
| US20040265335A1 (en) | Herbal composition and method of treating HIV infection | |
| KR100370501B1 (en) | Composition for treatment of hepatitis b, containing extract of lonicera japonica thunb | |
| Julius Moshi et al. | Antimycobacterial Activity and Brine Shrimp Toxicity of Wild Mushrooms Used by Communities in Southern Tanzania | |
| WO2004062679A1 (en) | Zanthoxylum spp. plant extracts for treating aids | |
| KR100193216B1 (en) | Treatment of acquired immunodeficiency syndrome containing mixed water extracts of Hwangbaekpi and Matari plants | |
| ZA200604983B (en) | Pharmaceutical composition which can be used in particular as an antiviral, antibacterial and for stimulating the immune defences |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |